In the Phase 1b trials there were some audiogram improvements but they only went up to 8 kHz. Hopefully with the Phase 2b trials they go up to 20 kHz with audiograms and we should see more people with audiogram improvements.
HF Audiograms go up to 16 kHz. Above that, and the tools become unreliable. Based on their most recent diagram showing FX-322 penetration into the cochlea, it looks like there may be some improvement from 12 kHz - 16 kHz.In the Phase 1b trials there were some audiogram improvements but they only went up to 8 kHz. Hopefully with the Phase 2b trials they go up to 20 kHz with audiograms and we should see more people with audiogram improvements.
I don't see FREQ going bankrupt. Too much promise in their technology & patents both in and out of the hearing space. Progenitor cell activation for MS works as evidenced by multiple Phase 2 clinical trials from multiple educational institutions. I'm confident there MS drug will work, I'm only hesitant about what side effects it may cause and if that could prevent it from making it to market.Would OTIC and FREQ rather go bankrupt than start working together...? Anyone think they might vanish before 2025?
I don't see FREQ going bankrupt. Too much promise in their technology & patents both in and out of the hearing space. Progenitor cell activation for MS works as evidenced by multiple Phase 2 clinical trials from multiple educational institutions. I'm confident there MS drug will work, I'm only hesitant about what side effects it may cause and if that could prevent it from making it to market.
Doesn't seem that great results, or is it just me?Press Release said:To gain a more comprehensive understanding of the potential impact of FX-322 in this population, the Company evaluated hearing function using multiple tests of speech perception in both quiet and noisy backgrounds, including the Bamford-Kowal-Bench Sentence-in-Noise exam (BKB-SIN). BKB-SIN is a validated test designed for severe SNHL populations (including cochlear implant patients), measuring the change in signal-to-noise ratios (SNR) required for a subject to correctly repeat words in a sentence.
In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95 percent critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response. A single placebo patient had a 3.6 dB change. In the study, subjects did not show substantial changes in speech perception measures in quiet, the safety profile in the study was favorable and there were no treatment-related serious adverse events reported.
Considering that everyone on this thread thought that there'd be no positive news coming from the severe trial, it's actually pretty positive and a step in the right direction.Doesn't seem that great results, or is it just me?
Science is iterative. Has any treatment before yielded these results? FX-322 is a start. FX-345 might do more.I am not sure if I am reading this correctly: 4 out of 31 participants experienced 3 to 6 dB improvement? Are they really calling these "promising results"? It sounds like a joke to me.
4/25 got drug. 6 got placebo.I am not sure if I am reading this correctly: 4 out of 31 participants experienced 3 to 6 dB improvement? Are they really calling these "promising results"? It sounds like a joke to me.
They state the patient/placebo ratio is 4:1, so there were 25 FX-322 patients and 6 placebo patients. 4/25 (16%) of the FX-322 group saw an improvement and 1/6 (16.6%) of the placebo group saw an improvement. They also state that the improvement was seen in a sound in noise test and don't say anything about a words in quiet test (was there no improvement in words in quiet?). I believe they only checked 1 time point too (90 day).Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
Does this read that 4 out of 31 saw some improvement? Is this good?
2 things:I am not sure if I am reading this correctly: 4 out of 31 participants experienced 3 to 6 dB improvement? Are they really calling these "promising results"? It sounds like a joke to me.
I don't think it's fair to make the comparison to OTO-413 without knowing how deep OTO-413 is penetrating the cochlea. If OTO-413 is reaching the apex while FX-322 is barely reaching the base, that is comparing apples to oranges. The 4 Severe patients saw improvement when FX-322 "treated" only the top 20% of the patient's cochlea while leaving the bottom 80% untouched.These results seem pretty grim to me. They're also significantly weaker than OTO-413's Phase 1 results (though in fairness that study was smaller), which is geared towards improving hearing in noise.
For some perspective, here is the visualization that they had previously been using for FX-322 (as recently as this past summer):2 things:
First is the numbers. It's not 4 out of 31, it's 4 out of 25 as 6 of them got placebo.
Secondly, remember that FX-322 is barely touching the base of the cochlea (as shaded in orange). The fact that 4 patients saw an improvement when they have Severe hearing loss and you are "treating" only the top 15% to 20% of their hearing range while leaving the remaining 80% of their hearing untouched, it is actually pretty promising.
View attachment 48153
It also bodes well for FX-345 (shaded in purple) as it targets the exact same pathways as 322 but is able to penetrate deeper based on the more potent GSK3 inhibitor. In my opinion, these hit and miss improvements between patients are a result of poor cochlear penetration and not a failed mechanism of action of the drug. It appears that the drug works and just needs to get deeper.
For some perspective, here is the visualization that they had previously been using for FX-322 (as recently as this past summer):
I'm confused because I don't understand the basics clearly.I wonder why they don't use some high frequency audiogram testing, since they know how far in the cochlea this substance can reach. If it truly regenerated something in there, wouldn't the ability to hear 10 kHz-20kHz sounds come back? I'm no expert of course, but the whole thing about FX-322 looks so off since the beginning.
Frequency has said that in their preclinical noise damaged mice models they were able to restore hearing function, I believe they measure it via brainstem response but I could be wrong.Were there any articles in animal experiments that they improved hearing in hearing-impaired mice? Was it an article about hair cell regeneration, not hearing restoration?
Has anyone seen an article about hearing restores on all frequencies with a mouse? I feel like I've seen a post with such a quote.
I don't know a lot to be honest, but they (Frequency Therapeutics) proudly use images of cochleas that have renewed lines of cells. I believe it's from mice since they are not allowed to dissect a human cochlea. Hair cell regeneration shouldn't be too far from hearing restoration, but there are synapses and other nerves in there. But I'm sure there were articles about hearing impaired mice that got their hearing restored.Were there any articles in animal experiments that they improved hearing in hearing-impaired mice? Was it an article about hair cell regeneration, not hearing restoration?
Reality.That is interesting, I hadn't seen much of that image showing FX-322 getting down to 4,000Hz. So it appears that they keep showing FX-322 reaching less & less area with each updated visualization. I'm curious what research & data caused them to do that.
I think that the truth may not be known without animal experiments with mammals that are closer to humans than mice.I don't know a lot to be honest, but they (Frequency Therapeutics) proudly use images of cochleas that have renewed lines of cells. I believe it's from mice since they are not allowed to dissect a human cochlea.
For that reason, I'm worried whether the video that FX-345 penetrates deeper is true.That is interesting, I hadn't seen much of that image showing FX-322 getting down to 4,000Hz. So it appears that they keep showing FX-322 reaching less & less area with each updated visualization. I'm curious what research & data caused them to do that.
Chimpanzees in Laboratories | PETAI think that the truth may not be known without animal experiments with mammals that are closer to humans than mice.
But I don't know what kind of animal it is.
Is it only a mouse in the animal experiment of FX-345? I think that's not enough.
Exactly. People in this thread are wondering why the results weren't that good and we have to remember this is for participants who have severe hearing loss. We also have to remember that the difference in hearing improvements had to be 3.1 dB or greater. For all we know there may have been more patients who were near a 3.1 dB improvement but unfortunately Frequency Therapeutics aren't going to say the improvements for each patient.Considering that everyone on this thread thought that there'd be no positive news coming from the severe trial, it's actually pretty positive and a step in the right direction.
To be honest, I don't know and understand how significant a 3.1 dB or 6 dB improvement with BKB-SIN is for patients with severe hearing loss.Exactly. People in this thread are wondering why the results weren't that good and we have to remember this is for participants who have severe hearing loss. We also have to remember that the difference in hearing improvements had to be 3.1 dB or greater. For all we know there may have been more patients who were near a 3.1 dB improvement but unfortunately Frequency Therapeutics aren't going to say the improvements for each patient.
But if 4/25 in the severe hearing loss had a 3.1 dB improvement in hearing or greater in certain frequencies then imagine what the mild-moderately severe hearing loss patients results will look like end of next year.
This may be enough to get rid of tinnitus permanently.